collection
MENU ▼
Read by QxMD icon Read
search

BMT

shared collection
38 papers 0 to 25 followers
https://www.readbyqxmd.com/read/28499938/allogeneic-stem-cell-transplantation-in-myelofibrosis
#1
REVIEW
Tania Jain, Ruben A Mesa, Jeanne M Palmer
Myeloproliferative neoplasm (MPN) is a category in the World Health Organization classification of myeloid tumors. BCR-ABL1-negative MPN is a subcategory that includes primary myelofibrosis (MF), post-essential thrombocythemia MF, and post-polycythemia vera MF. These disorders are characterized by stem cell-derived clonal myeloproliferation. Clinically, these diseases present with anemia and splenomegaly and significant constitutional symptoms such as severe fatigue, symptoms associated with an enlarged spleen and liver, pruritus, fevers, night sweats, and bone pain...
May 10, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28504666/conditioning-regimens-for-allogeneic-hematopoietic-stem-cell-transplants-in-acute-myeloid-leukemia
#2
REVIEW
Y S Jethava, S Sica, B Savani, F Socola, M Jagasia, M Mohty, A Nagler, A Bacigalupo
AML is currently the first indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT), as shown by international transplant registries. The conditioning regimens are classified as myeloablative conditioning, non-myeloablative or reduced intensity conditioning. Targeted radioimmunotherapy such as anti-CD45 antibody have also been added to the conditioning regimen in an attempt to improve tumor cell kill. Refinement of standard regimens has led to a reduction of non-relapse mortality, also in the older age group over 60 or 70 years of age...
May 15, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28487480/microbiota-promotes-systemic-t-cell-survival-through-suppression-of-an-apoptotic-factor
#3
Raymond Soto, Charisse Petersen, Camille L Novis, Jason L Kubinak, Rickesha Bell, W Zac Stephens, Thomas E Lane, Robert S Fujinami, Alberto Bosque, Ryan M O'Connell, June L Round
Symbiotic microbes impact the severity of a variety of diseases through regulation of T-cell development. However, little is known regarding the molecular mechanisms by which this is accomplished. Here we report that a secreted factor, Erdr1, is regulated by the microbiota to control T-cell apoptosis. Erdr1 expression was identified by transcriptome analysis to be elevated in splenic T cells from germfree and antibiotic-treated mice. Suppression of Erdr1 depends on detection of circulating microbial products by Toll-like receptors on T cells, and this regulation is conserved in human T cells...
May 23, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28506845/ex-vivo-mesenchymal-precursor-cell-expanded-cord-blood-transplantation-following-reduced-intensity-conditioning-regimens-improves-time-to-neutrophil-recovery
#4
Rohtesh S Mehta, Rima M Saliba, Kai Cao, Indreshpal Kaur, Katy Rezvani, Julianne Chen, Amanda Olson, Simrit Parmar, Nina Shah, David Marin, Amin Alousi, Chitra Hosing, Uday Popat, Partow Kebriaei, Richard Champlin, Marcos de Lima, Donna Skerrett, Elizabeth Burke, Elizabeth J Shpall, Betul Oran
We previously showed the safety of using cord blood (CB) expanded ex vivo in cocultures with allogeneic mesenchymal precursor cells (MPC) after myeloablative conditioning with faster recovery of neutrophils and platelets compared with historical controls. Herein, we report the transplant outcomes of 27 patients with hematologic cancers who received one CB unit ex vivo expanded with MPCs in addition to an unmanipulated CB (MPC group) after reduced intensity conditioning (RIC). The results in this group were compared with 51 historical controls who received two unmanipulated CB units (control group)...
May 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28487696/natural-killer-cells-in-graft-versus-host-disease-after-allogeneic-hematopoietic-cell-transplantation
#5
REVIEW
Federico Simonetta, Maite Alvarez, Robert S Negrin
Allogeneic hematopoietic cell transplantation (HCT) is a well-established therapeutic modality effective for a variety of hematological malignancies but, unfortunately, is associated with significant morbidity and mortality related to cancer relapse as well as to transplant-related complications including graft-versus-host-disease (GvHD). Natural killer (NK) cells are the first donor-derived lymphocyte subset to recover after HCT, and their crucial role in protection against cancer relapse and infections is well established...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28395942/ex-vivo-t-cell-depleted-allogeneic-stem-cell-transplantation-for-hematologic-malignancies-the-search-for-an-optimum-transplant-t-cell-dose-and-t-cell-add-back-strategy
#6
Prathima Anandi, Xin Tian, Sawa Ito, Pawel Muranski, Puja D Chokshi, Noelle Watters, Upneet Chawla, Nancy Hensel, David F Stroncek, Minoo Battiwalla, A John Barrett
BACKGROUND: T-cell depletion (TCD) of allogeneic stem cell transplants (SCT) can reduce graft-versus-host disease but may negatively affect transplant outcome by delaying immune recovery. To optimize TCD in HLA-matched siblings with hematologic malignancies, we explored varying the transplant CD3+ T-cell dose between 2 and 50 × 10(4)/kg (corresponding to 3-4 log depletion) and studied the impact of 0-6 × 10(7)/kg CD3+ donor lymphocyte infusion (DLI) "add-back" on immune recovery post-SCT...
April 7, 2017: Cytotherapy
https://www.readbyqxmd.com/read/28092347/haploidentical-transplantation-with-post-infusion-cyclophosphamide-in-advanced-hodgkin-lymphoma
#7
L Castagna, S Bramanti, R Devillier, B Sarina, R Crocchiolo, S Furst, J El-Cheikh, A Granata, C Faucher, S Harbi, L Morabito, J Mariotti, S Puvinathan, P J Weiller, C Chabannon, D Mokart, C Carlo-Stella, R Bouabdallah, A Santoro, D Blaise
We investigated the use of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) in the treatment of advanced Hodgkin lymphoma (HL). Sixty-two consecutive HL patients underwent haplo-HSCT. Unmanipulated stem cells and post-transplant cyclophosphamide were given to all patients as GVHD prophylaxis. At 100 days, the cumulative incidence of grades 2-3 and grades 3-4 acute GVHD was 23% and 4%, respectively. The chronic GVHD (cGVHD) cumulative incidence was 16%, with one patient experiencing severe cGVHD...
January 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28465624/haploidentical-transplantation-with-post-infusion-cyclophosphamide-in-advanced-hodgkin-lymphoma
#8
L Castagna, S Bramanti, R Devillier, B Sarina, R Crocchiolo, S Furst, J El-Cheikh, A Granata, C Faucher, S Harbi, L Morabito, J Mariotti, S Puvinathan, P J Weiller, C Chabannon, D Mokart, C Carlo-Stella, R Bouabdallah, A Santoro, D Blaise
No abstract text is available yet for this article.
May 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28369779/allogeneic-stem-cell-transplantation-in-patients-with-atypical-chronic-myeloid-leukaemia-a-retrospective-study-from-the-chronic-malignancies-working-party-of-the-european-society-for-blood-and-marrow-transplantation
#9
Francesco Onida, Liesbeth C de Wreede, Anja van Biezen, Diderik-Jan Eikema, Jenny L Byrne, Anna P Iori, Rik Schots, Alexandra Jungova, Johannes Schetelig, Jürgen Finke, Hendrik Veelken, Jan-Erik Johansson, Charles Craddock, Matthias Stelljes, Matthias Theobald, Ernst Holler, Urs Schanz, Nicolaas Schaap, Jörg Bittenbring, Eduardo Olavarria, Yves Chalandon, Nicolaus Kröger
Atypical chronic myeloid leukaemia (aCML) is an aggressive malignancy for which allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents the only curative option. We describe transplant outcomes in 42 patients reported to the European Society for Blood and Marrow Transplantation (EBMT) registry who underwent allo-HSCT for aCML between 1997 and 2006. Median age was 46 years. Median time from diagnosis to transplant was 7 months. Disease status was first chronic phase in 69%. Donors were human leucocyte antigen (HLA)-identical siblings in 64% and matched unrelated (MUD) in 36%...
June 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28380315/myeloablative-versus-reduced-intensity-hematopoietic-cell-transplantation-for-acute-myeloid-leukemia-and-myelodysplastic-syndromes
#10
Bart L Scott, Marcelo C Pasquini, Brent R Logan, Juan Wu, Steven M Devine, David L Porter, Richard T Maziarz, Erica D Warlick, Hugo F Fernandez, Edwin P Alyea, Mehdi Hamadani, Asad Bashey, Sergio Giralt, Nancy L Geller, Eric Leifer, Jennifer Le-Rademacher, Adam M Mendizabal, Mary M Horowitz, H Joachim Deeg, Mitchell E Horwitz
Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia or myelodysplastic syndromes. Patients and Methods Patients age 18 to 65 years with HCT comorbidity index ≤ 4 and < 5% marrow myeloblasts pre-HCT were randomly assigned to receive MAC (n = 135) or RIC (n = 137) followed by HCT from HLA-matched related or unrelated donors...
April 10, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28296583/relationship-between-intestinal-bacteria-and-the-anticancer-effect-of-hematopoietic-stem-cell-transplantation
#11
Joseph H Antin
No abstract text is available yet for this article.
March 15, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28296584/intestinal-microbiota-and-relapse-after-hematopoietic-cell-transplantation
#12
Jonathan U Peled, Sean M Devlin, Anna Staffas, Melissa Lumish, Raya Khanin, Eric R Littmann, Lilan Ling, Satyajit Kosuri, Molly Maloy, John B Slingerland, Katya F Ahr, Kori A Porosnicu Rodriguez, Yusuke Shono, Ann E Slingerland, Melissa D Docampo, Anthony D Sung, Daniela Weber, Amin M Alousi, Boglarka Gyurkocza, Doris M Ponce, Juliet N Barker, Miguel-Angel Perales, Sergio A Giralt, Ying Taur, Eric G Pamer, Robert R Jenq, Marcel R M van den Brink
Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT) are relapse, graft-versus-host disease (GVHD), and infection. We have reported previously that alterations in the intestinal flora are associated with GVHD, bacteremia, and reduced overall survival after allo-HCT. Because intestinal bacteria are potent modulators of systemic immune responses, including antitumor effects, we hypothesized that components of the intestinal flora could be associated with relapse after allo-HCT...
May 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28292947/mobilization-of-allogeneic-peripheral-blood-stem-cell-donors-with-intravenous-plerixafor-mobilizes-a-unique-graft
#13
Mark A Schroeder, Michael P Rettig, Sandra Lopez, Stephanie Christ, Mark Fiala, William Eades, Fazia A Mir, Jin Shao, Kyle McFarland, Kathryn Trinkaus, William Shannon, Elena Deych, Jinsheng Yu, Ravi Vij, Keith Stockerl-Goldstein, Amanda F Cashen, Geoffrey L Uy, Camille N Abboud, Peter Westervelt, John F DiPersio
A single subcutaneous (SC) injection of plerixafor results in rapid mobilization of hematopoietic progenitors, but fails to mobilize 33% of normal allogeneic sibling donors in 1 apheresis. We hypothesized that changing the route of administration of plerixafor from SC to IV may overcome the low stem cell yields and allow collection in 1 day. A phase 1 trial followed by a phase 2 efficacy trial was conducted in allogeneic sibling donors. The optimal dose of IV plerixafor was determined to be 0.32 mg/kg. The primary outcome of reducing the failure to collect ≥2 × 10(6) CD34(+)/kg recipient weight in 1 apheresis collection to ≤10% was not reached...
May 11, 2017: Blood
https://www.readbyqxmd.com/read/27856461/how-i-treat-bronchiolitis-obliterans-syndrome-after-hematopoietic-stem-cell-transplantation
#14
REVIEW
Kirsten M Williams
In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortality secondary to lack of consensus for diagnostic criteria, poorly understood disease pathogenesis, and very few studies of therapeutic or supportive care interventions. Recently, however, progress has been made in these areas: revised consensus diagnostic guidelines are now available, supportive care has improved, there is greater understanding of potential mechanisms of disease, and prospective trials are being conducted...
January 26, 2017: Blood
https://www.readbyqxmd.com/read/27856471/role-of-the-intestinal-mucosa-in-acute-gastrointestinal-gvhd
#15
REVIEW
Jonathan U Peled, Alan M Hanash, Robert R Jenq
Intestinal graft-versus-host disease (GVHD) remains a significant obstacle to the success of allogeneic hematopoietic cell transplantation. The intestinal mucosa comprises the inner lining of the intestinal tract and maintains close proximity with commensal microbes that reside within the intestinal lumen. Recent advances have significantly improved our understanding of the interactions between the intestinal mucosa and the enteric microbiota. Changes in host mucosal tissue and commensals posttransplant have been actively investigated, and provocative insights into mucosal immunity and the enteric microbiota are now being translated into clinical trials of novel approaches for preventing and treating acute GVHD...
November 17, 2016: Blood
https://www.readbyqxmd.com/read/27940475/the-intestinal-microbiota-in-allogeneic-hematopoietic-cell-transplant-and-graft-versus-host-disease
#16
REVIEW
Anna Staffas, Marina Burgos da Silva, Marcel R M van den Brink
Hematopoietic cell transplantation (HCT) is a critical treatment of patients with high-risk hematopoietic malignancies, hematological deficiencies, and other immune diseases. In allogeneic HCT (allo-HCT), donor-derived T cells recognize host tissues as foreign, causing graft-versus-host disease (GVHD) which is a main contributor to morbidity and mortality. The intestine is one of the organs most severely affected by GVHD and research has recently highlighted the importance of bacteria, particularly the gut microbiota, in HCT outcome and in GVHD development...
February 23, 2017: Blood
https://www.readbyqxmd.com/read/28137828/acute-graft-versus-host-disease-is-regulated-by-an-il-17-sensitive-microbiome
#17
Antiopi Varelias, Kate L Ormerod, Mark D Bunting, Motoko Koyama, Kate H Gartlan, Rachel D Kuns, Nancy Lachner, Kelly R Locke, Chun Y Lim, Andrea S Henden, Ping Zhang, Andrew D Clouston, Sumaira Z Hasnain, Michael A McGuckin, Bruce R Blazar, Kelli P A MacDonald, Philip Hugenholtz, Geoffrey R Hill
Donor T-cell-derived interleukin-17A (IL-17A) can mediate late immunopathology in graft-versus-host disease (GVHD), however protective roles remain unclear. Using multiple cytokine and cytokine receptor subunit knockout mice, we demonstrate that stem cell transplant recipients lacking the ability to generate or signal IL-17 develop intestinal hyper-acute GVHD. This protective effect is restricted to the molecular interaction of IL-17A and/or IL-17F with the IL-17 receptor A/C (IL-17RA/C). The protection from GVHD afforded by IL-17A required secretion from, and signaling in, both hematopoietic and nonhematopoietic host tissue...
April 13, 2017: Blood
https://www.readbyqxmd.com/read/28157678/fit-for-cure-microbiota-and-gvhd
#18
Ernst Holler, Daniela Weber
No abstract text is available yet for this article.
October 20, 2016: Blood
https://www.readbyqxmd.com/read/28157682/fecal-microbiota-transplantation-for-agvhd-of-the-gut
#19
(no author information available yet)
No abstract text is available yet for this article.
October 20, 2016: Blood
https://www.readbyqxmd.com/read/28255020/impact-of-abo-incompatibility-on-patients-outcome-after-haploidentical-hematopoietic-stem-cell-transplantation-for-acute-myeloid-leukemia-a-report-from-the-acute-leukemia-working-party-of-the-ebmt
#20
Jonathan Canaani, Bipin N Savani, Myriam Labopin, Xiao-Jun Huang, Fabio Ciceri, William Arcese, Johanna Tischer, Yener Koc, Benedetto Bruno, Zafer Gülbas, Didier Blaise, Johan Maertens, Gerhard Ehninger, Mohamad Mohty, Arnon Nagler
A significant proportion of hematopoietic stem cell transplants are performed with ABO-mismatched donors. The impact of ABO mismatch on outcome following transplantation remains controversial and there are no published data regarding the impact of ABO mismatch in acute myeloid leukemia patients receiving haploidentical transplants. Using the European Blood and Marrow Transplant Acute Leukemia Working Group registry we identified 837 patients who underwent haploidentical transplantation. Comparative analysis was performed between patients who received ABO-matched versus ABO-mismatched haploidentical transplants for common clinical outcome variables...
June 2017: Haematologica
label_collection
label_collection
7701
1
2
2017-03-16 02:06:30
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"